Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.62 |
| ▸ | POLB | P06746 | 9/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | BLM | P54132 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 5/20 | 0.57 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183133 | 1.00 | MEN1 (0.62) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL13567557 | 1.00 | MEN1 (0.62) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL624098 | 0.84 | MEN1 (0.55) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL624099 | 0.84 | MEN1 (0.55) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL5139092 | 0.84 | MEN1 (0.59) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL5139089 | 0.84 | MEN1 (0.59) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL5139091 | 0.84 | MEN1 (0.59) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL6782912 | 0.74 | HPGD (0.50) | MEN1KMT2APOLBHPGDRAB9A | |
| SCHEMBL211085 | 0.73 | PIM1 (1.00) | HPGDRAB9ATDP1PIM1PIM2 | |
| SCHEMBL1250387 | 0.73 | PIM1 (1.00) | HPGDRAB9ATDP1PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120909-A2 | TREATMENTS OF THERAPY-RESISTANT DISEASES COMPRISING DRUG COMBINATIONS | Ordway Research Institute (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080312199-A1 | Treatments of therapy resistant diseases and drug combinations for treating the same | ORDWAY RESEARCH INSTITUTE, INC. | 2008-12-18 | — | — | US | claimed |
| WO-2008076447-A2 | TREATMENTS OF THERAPY-RESISTANT DISEASES COMPRISING DRUG COMBINATIONS | ORDWAY RESEARCH INSTITUTE (US) | 2008-06-26 | — | — | WO | claimed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2021-06-24 | — | — | US | disclosed |
| US-10934528-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-02 | — | — | US | disclosed |
| US-10308912-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3399026-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-2580320-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170159019-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2017-06-08 | — | — | US | disclosed |
| US-9556417-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2011159726-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | WO | disclosed |
| CN-102271708-A | CD37 immunotherapeutic combination therapies and uses thereof | — | 2011-12-07 | — | — | CN | disclosed |
| EP-2358390-A1 | CD37 IMMUNOTHERAPEUTIC COMBINATION THERAPIES AND USES THEREOF | Emergent Product Development Seattle, LLC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100135900-A1 | CD37 IMMUNOTHERAPEUTIC COMBINATION THERAPIES AND USES THEREOF | TRUBION PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010057047-A1 | CD37 IMMUNOTHERAPEUTIC COMBINATION THERAPIES AND USES THEREOF | TRUBION PHARMACEUTICS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2120909-A2 | TREATMENTS OF THERAPY-RESISTANT DISEASES COMPRISING DRUG COMBINATIONS | Ordway Research Institute (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080312199-A1 | Treatments of therapy resistant diseases and drug combinations for treating the same | ORDWAY RESEARCH INSTITUTE, INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008076447-A2 | TREATMENTS OF THERAPY-RESISTANT DISEASES COMPRISING DRUG COMBINATIONS | ORDWAY RESEARCH INSTITUTE (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2000018746-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934528-B2 | Reprogramming of cells to a new fate | ALPG, POU5F1, POU2F1 | MEN1 2207/4885KMT2A 542/4885POLB 3949/4885 |
| US-20170159019-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | ALPG, POU5F1, POU2F1 | MEN1 2207/4885KMT2A 542/4885POLB 3949/4885 |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | ALPG, POU5F1, POU2F1 | MEN1 2207/4885KMT2A 542/4885POLB 3949/4885 |
| US-10308912-B2 | Reprogramming of cells to a new fate | ALPG, POU5F1, POU2F1 | MEN1 2207/4885KMT2A 542/4885POLB 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.